Background
The treatment of migraine remains an important and challenging task. In a substantial part of patients with episodic migraine (EM), and nearly all patients with chronic migraine (CM), next to an adequate acute medication strategy, a preventive treatment is indicated. Several drugs are currently available for migraine prevention but studies show poor adherence to oral migraine prophylactics [
1‐
4]. Adverse events are cited as the most common reason for discontinuation, next to lack of efficacy. The main causes for their lack of high efficacy and poor tolerability are considered related to the fact that they were not specifically developed for migraine and that most of them have multiple mechanisms of action [
5,
6].
The presence of calcitonin gene-related peptide (CGRP) in the trigeminovascular system, the observation of CGRP release during the headache phase of a migraine attack and the induction of a migraine-like headache after intravenous administration of exogenous CGRP, have led to the assumption that CGRP plays a major role in the pathophysiology of migraine [
7]. The discovery of this new drug target resulted in the development of the first disease-specific preventive treatment class for both EM and CM, being monoclonal antibodies against the CGRP molecule (eptinezumab, fremanezumab and galcanezumab) or its receptor complex (erenumab) (CGRP mAb).
Over the past few years, several clinical trials with CGRP mAb for the preventive treatment of EM [
8‐
21] and CM [
14,
22‐
27] were performed worldwide. Safety and efficacy results were consistently convincing, resulting in the approval of erenumab, fremanezumab and galcanezumab by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the preventive treatment of EM and CM in adults in 2018 and 2019. Eptinezumab received FDA approval in February 2020.
The positioning of these new drugs in the preventive treatment strategy of EM and CM compared to the currently used prophylactic agents remains unclear, since no results from head-to-head trials are yet available. It was already suggested in a recent review that the major added value of the CGRP mAb might be their more favorable efficacy over adverse event profile [
28]. The objective of this manuscript is to present a comprehensive overview on currently available results of all four CGRP mAb for the treatment of EM and CM. Secondly, these results are put into perspective next to the available evidence from the most widely used agents for the prevention of EM and CM with an emphasis on efficacy, the robustness of this efficacy signal and tolerability.
Methods
Selection of prophylactic migraine drugs
As for the currently used prophylactic agents in EM and CM, only those with a level A evidence as determined by either the European Federation of Neurological Societies (EFNS) [
29] or American Academy of Neurology (AAN) [
30] were included. Candesartan and amitriptyline were added because they are first line treatments for migraine in several countries. Besides, for both agents a relevant clinical trial was published after the aforementioned guidelines were assembled [
31,
32]. Flunarizine was not included in the final analysis despite its level A recommendation in the EFNS guideline. The main reasons are its unavailability in several countries and the fact that the endpoint used in the present manuscript could not be retrieved from any of the performed clinical trials. Timolol also has a level A evidence for the treatment of EM according to the AAN guideline, but not in the EFNS guideline. Since its evidence is considered to be less convincing compared to propranolol and metoprolol [
29], and the fact that oral timolol is not available in several European countries, it was not included in the final analysis. As such, the following drugs were selected: propranolol, metoprolol, onabotulinumtoxinA, topiramate, valproate, candesartan and amitriptyline.
Search methodology
For the currently used prophylactic agents, potential clinical trials were identified by searching the PubMed and Cochrane Library databases (until the 1st of September, 2021). In addition, reference lists of included studies and relevant reviews or meta-analyses were manually screened to identify additional studies that were not found by the computerized search. As for the CGRP mAb, an additional database search on clinicaltrials.gov was performed using the following terms: TEV-48125 or fremanezumab, LY2951742 or galcanezumab, ALD403 or eptinezumab and AMG334 or erenumab. The study search was performed by FVDV, in case of doubt consensus was sought between JV and FVDV.
Clinical trial selection
Only trials in adults with a randomized (parallel group or cross-over) double-blinded placebo-controlled design studying the efficacy of an agent in monotherapy, of which the full article was available in English, with at least 10 patients in each treatment arm and reporting of the administered dosages were considered. Studies were selected based on title and abstract but deemed suitable for inclusion only after a full-text review.
Outcome measures
Efficacy
The mean reduction of monthly migraine days (MMD) versus placebo was selected as the efficacy endpoint of choice, since it was the primary endpoint in most of the CGRP mAb trials and could be extracted from at least one clinical trial for every other prophylactic agent under study. Moreover, this endpoint was put forward by the International Headache Society (IHS) as one of the primary efficacy measures of choice in drug trials for migraine prophylaxis [
33]. If the MMD was calculated at different time points in a trial, only the latest reported was used unless the primary endpoint was set at a different time point.
Results from all 4 CGRP mAb were lumped, considering their comparable mechanism of action and the fact that so far no clear difference in efficacy appears from clinical trials although no head-to-head trials have been performed. Trials with CGRP mAb including patients with difficult to treat migraine were not included in the MMD reduction analysis since no comparable trials are available with the classic prophylactic drugs used for migraine. Since different dosages and dosing regimens were used for every agent, only one dosage was selected per agent for the MMD calculation in order to be consistent. As such, the following dosages were chosen: eptinezumab 300 mg, erenumab 140 mg, fremanezumab 225 mg monthly (with or without loading dose), and galcanezumab 120 mg monthly with a 240 mg loading dose (indicated in bold in Table
1 and
2).
Table 1
Results of randomized placebo-controlled clinical trials with CGRP mAb for the treatment of episodic migraine
Eptinezumab | II | ≥5 | - | 8 | placebo | 82 | | 0% | Dodick et al, 2014 | NCT01772524 |
1000mg | 81 | -1.0 | 0% |
III | ≥4 | - | 12 | placebo | 222 | | 3% | Ashina et al, 2020 | PROMISE-1 |
100mg | 221 | -0.7 | 3% |
300mg | 222 | -1.1 | 2% |
Fremanezumab | II | ≥8 | >2 | 12 | placebo | 104 | | 0% | Bigal et al, 2015 | NCT02025556 |
225mg | 96 | -2.8 | 4% |
675mg monthly | 96 | -2.6 | 2% |
III | ≥4 | ≥2 | 12 | placebo | 294 | | 2% | Dodick et al, 2018 | HALO |
225mg | 289 | -1.5 | 1% |
675mg | 291 | -1.3 | 2% |
II/III | ≥4 | ≥2 | 12 | placebo | 117 | | 1% | Sakai et al, 2021 | NCT03303092 |
225mg | 121 | -3.0 | 1% |
675mg | 119 | -3.0 | 0% |
Galcanezumab | II | ≥4 | >2 | 12 | placebo | 110 | | 1% | Dodick et al, 2014 | NCT01625988 |
150mg every 2 weeks | 107 | -1.2 | 0% |
II | ≥4 | >2 | 12 | placebo | 137 | | 0% | Sklajarevski et al, 2018 | NCT02163993 |
120mg | 70 | -0.9 | 0% |
300mg | 67 | -0.9 | 1% |
III | ≥4 | >2 | 24 | placebo | 433 | | 2% | Stauffer et al, 2018 | EVOLVE-1 |
120mg (a240mg) | 213 | -1.9 | 4% |
240mg | 212 | -1.8 | 3% |
III | ≥4 | >2 | 24 | placebo | 461 | | 2% | Sklajarevski et al, 2018 | EVOLVE-2 |
120mg (a240mg) | 231 | -2.0 | 2% |
240mg | 223 | -1.9 | 4% |
Erenumab | II | ≥4 | >2 | 12 | placebo | 153 | | 1% | Sun et al, 2016 | NCT01952574 |
70mg | 106 | -1.1 | 3% |
II | ≥4 | >2 | 24 | placebo | 136 | | 1% | Sakai et al, 2019 | NCT02630459 |
70mg | 135 | -2.3 | 1% |
140mg | 137 | -1.9 | 0% |
III | ≥4 | >2 | 24 | placebo | 319 | | 3% | Goadsby et al, 2017 | STRIVE |
70mg | 314 | -1.4 | 2% |
140mg | 319 | -1.9 | 2% |
III | ≥4 | >2 | 12 | placebo | 289 | | 0% | Dodick et al, 2018 | ARISE |
70mg | 283 | -1.0 | 2% |
III | ≥4 | >2 | 12 | placebo | 338 | | 1% | Wang et al, 2021 | EMPOwER |
70mg | 338 | -1.1 | 0% |
140mg | 224 | -1.7 | 0% |
Table 2
Results of randomized placebo-controlled clinical trials with CGRP mAb for the treatment of chronic migraine
Eptinezumab | II | - | - | 12 | placebo | 121 | | 0 | 0% | Dodick et al, 2019 | NCT02275117 |
100mg | 123 | -2.1 | 2 | 2% |
300mg | 120 | -2.6 | 4 | 3% |
III | + | - | 12 | placebo | 366 | | 2 | 1% | Lipton et al, 2020 | PROMISE-2 |
100mg | 356 | -2.0 | 3 | 1% |
300mg | 350 | -2.6 | 8 | 2% |
Fremanezumab | II | - | ≥3 | 12 | placebo | 89 | | 1 | 1% | Bigal et al, 2015 | NCT02021773 |
225mg (a675mg) | 88 | -1.7 | 4 | 5% |
900mg monthly | 86 | -2.0 | 3 | 3% |
III | + | ≥2 | 12 | placebo | 375 | | 8 | 2% | Silberstein et al, 2017 | HALO |
675mg | 376 | -1.7 | 5 | 1% |
225mg (a675mg) | 379 | -1.8 | 7 | 2% |
II/III | + | ≥2 | 12 | placebo | 191 | | 3 | 2% | Sakai et al, 2021 | NCT03303079 |
675mg | 191 | -1.3 | 1 | 1% |
225mg | 189 | -2.1 | 0 | 0% |
Galcanezumab | III | + | >3 | 12 | placebo | 558 | | 6 | 1% | Detke et al, 2018 | REGAIN |
120mg (a240mg) | 278 | -2.1 | 3 | 1% |
240mg | 277 | -1.9 | 2 | 1% |
Erenumab | II | + | >3 | 12 | placebo | 282 | | 2 | 1% | Tepper et al, 2017 | NCT02066415 |
70mg | 190 | -2.4 | 0 | 0% |
140mg | 188 | -2.4 | 2 | 1% |
For the standard prophylactics, if efficacy results from different dosages were available, only those from dosages commonly used in clinical practice were included. As such, efficacy results from the following daily dosages were used for the MMD calculation: propranolol 80-160 mg, metoprolol 100-200 mg, topiramate 100 mg for EM and 50-200 mg for CM, valproate 250-1500 mg, candesartan 8-16 mg, amitriptyline 25 mg and onabotulinumtoxinA at the injection sites and dosing according to the PREEMPT trials [
34]. Since there is not enough evidence that propranolol and metoprolol have a different efficacy profile, both agents were lumped in the final analysis (further referred to as beta-blockers).
The reduction in MMD versus placebo for every agent was calculated by averaging and weighing the MMD reduction according to the total number of patients in the respective trials (so larger trials contributed more to the final average MMD reduction). Only patients who entered the placebo-controlled phase of the study were counted, as such excluding screen failures during the screening or baseline phase.
Tolerability
For each clinical trial, dropout rates for both the active treatment and placebo arm were calculated, if available. Dropout rates were calculated as follows: the number of patients who discontinued the clinical trial due to side-effects between randomization and the time the primary endpoint was reached, divided by the total number of subjects who were randomized in the same treatment arm. The dropout rate for every prophylactic agent was calculated by summing all dropout rates across every trial (so larger trials contributed more to the final dropout rate).
The respective data extraction was independently performed by at least two authors (LVD, AVD and FV for the standard prophylactic drugs and JV and FV for the CGRP mAb). Any unclarities or disagreements were resolved by consensus between FV and JV.
Discussion
MMD reductions of all assessed prophylactic drugs in EM and CM compared to placebo varied between 0,9 and 2,2 days. When looking at EM and CM separately, the values range between 0,9 and 1,8 days for EM, and 1,9 and 2,2 days for CM. In both EM and CM, the highest MMD reduction was found for the CGRP mAb. The true clinical efficacy of CGRP mAb might even be higher since overall a high placebo response was reached in most of the trials probably related to their more invasive route of administration [
81]. However, whether this small difference reflects a clinically meaningful difference remains unclear, since a head-to-head statistical comparison of the studied prophylactic agents is limited by several factors.
First, there is an enormous variation in trial design. As such, the chosen efficacy parameter, MMD reduction, could not be retrieved in all trials of the currently used prophylactic drugs. In mainly the older trials, other efficacy parameters were used (for example migraine attacks). Indeed, MMD was only proposed in 1985 as an alternative efficacy endpoint for the number of migraine attacks [
82]. This heterogeneity of outcome measures is a well-known problem among drug trials dealing with migraine prophylaxis, rendering a formal quantitative meta-analysis not feasible.
Second, large differences in both the number of patients treated with the preventive agent and the number of trials performed were seen. The studied sample size ranged for example between 132 patients for candesartan and 3191 (CM) or 4632 (EM) for CGRP mAb. As for the number of trials performed, this ranged between only two (both onabotulinumtoxinA for CM and candesartan) and 22 for beta-blockers. This also limits a formal statistical comparison of prophylactic agents.
Third, a huge variation in methodological quality of included studies of the currently used prophylactic agents has been demonstrated [
83‐
86]. As such, only valproate, metoprolol, propranolol and topiramate have a level A recommendation for the treatment of EM [
29,
30]. However, even for those 4 prophylactic agents several possible biases were identified by previous meta-analyses [
83‐
86]. Recent meta-analyses evaluating the efficacy of CGRP mAb on the other hand showed that the trial quality assessment was consistently more homogeneous with an overall low risk of bias [
87‐
91].
Efficacy results from all CGRP mAb were lumped. One should however be aware of the important differences across trials, concerning amongst others the required and maximum number of headache days at baseline, the allowance of medication overuse, the number of previously failed or currently preventive agents allowed, study duration (varying between three and six months), the chosen primary endpoint and the way this was calculated, the definition of a migraine day, all this combined with different dosing schemes.
Among the currently used prophylactics, the highest dropout rates compared to placebo were seen in patients treated with amitriptyline, valproate or topiramate. These high dropout rates seem to be consistent with both clinical practice and with data about migraine prophylaxis adherence, in which a substantial higher rate of discontinuation was seen among patients treated with topiramate and amitriptyline compared to propranolol [
4]. One has to be aware however that the overall tolerability and safety story is not fully reflected by ‘dropouts due to side-effects’ in a clinical trial. As for the oral prophylactic drugs, side effects like depressive mood, weight changes or nephrolithiasis might not be completely captured during a clinical trial. Even so, the real-world side effect profile of CGRP mAb is an evolving area of research where for example the development of hypertension or worsening of preexisting hypertension due to erenumab needs to be further elucidated in the near future. Finally, the concurrent high overall dropout rates in the amitriptyline and topiramate trials is remarkable, and might reflect a lower trial quality although no firm conclusions can be drawn.
Conclusions
CGRP mAb have an efficacy which is at least comparable to the efficacy of the currently used preventive drugs where the robustness of this efficacy signal is substantiated by several randomized clinical trials each containing large numbers of patients. Because of their excellent tolerability and ease of use, the major added value of CGRP mAb, compared to the classical preventive anti-migraine drugs, seems therefore to be their unprecedented high efficacy over adverse effect profile. The high cost of CGRP mAb urges further research both exploring their cost-effectiveness and subgroups of patients who are likely to benefit most. Combining all this information with additional data concerning long term safety, can be of particular use to health policy makers in order to be able to provide guidelines on how to implement this new class of drugs in the prevention of EM and CM.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.